SEC Tracker
Get the app

Possible new Faeth Therapeutics shares

FTHDilution

Known so far: no new shares from the prospectus covers read · shelf room about $2.4M · not yet read: converts, ATM.

Shelf room

  • Room today about $2.4M
  • One third of float $2.4M ($7.1M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $2.4M on the S-3ASR of Jun 18, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $7.1M public float stated as of Jun 30, 2025, $2.4M, nothing sold off it in the last 12 months. Sources: S-3ASR Jun 18, 2026, effective Jun 18, 2026 · public float, as of Jun 30, 2025.

What could become new Faeth Therapeutics (FTH) shares: warrants and options and RSUs, each with the 10-Q, 10-K, S-3 or 424B filing it comes from.

Faeth Therapeutics dilution ladder

Every source of new shares on record, from the filings that created it.

25.8M outstanding; up to 30.3M fully diluted, +17%

  1. Outstandingas of Oct 30, 2026 (10-Q filed Nov 3) · share count on the cover page
    25.8M
  2. Warrants1,372, at $2185.0410-Q Nov 3, 2026 · securities left out of diluted EPS
    +1,372
  3. Options and RSUs4.4M options, 88 RSUs10-Q Nov 3, 2026 · securities left out of diluted EPS
    +4.4M

Not stated in the filings we read: an ATM program, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Nov 3, 2026.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

25.8M

Mar 2025 to Oct 2026: from 1.3M to 25.8M. Adjusted for the 1-for-20 reverse split by Jul 31, 2025: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.